These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

689 related items for PubMed ID: 19744600

  • 1. Involvement of gadolinium chelates in the mechanism of nephrogenic systemic fibrosis: an update.
    Idée JM, Port M, Dencausse A, Lancelot E, Corot C.
    Radiol Clin North Am; 2009 Sep; 47(5):855-69, vii. PubMed ID: 19744600
    [Abstract] [Full Text] [Related]

  • 2. Efficiency, thermodynamic and kinetic stability of marketed gadolinium chelates and their possible clinical consequences: a critical review.
    Port M, Idée JM, Medina C, Robic C, Sabatou M, Corot C.
    Biometals; 2008 Aug; 21(4):469-90. PubMed ID: 18344005
    [Abstract] [Full Text] [Related]

  • 3. Possible involvement of gadolinium chelates in the pathophysiology of nephrogenic systemic fibrosis: a critical review.
    Idée JM, Port M, Medina C, Lancelot E, Fayoux E, Ballet S, Corot C.
    Toxicology; 2008 Jun 27; 248(2-3):77-88. PubMed ID: 18440117
    [Abstract] [Full Text] [Related]

  • 4. Role of thermodynamic and kinetic parameters in gadolinium chelate stability.
    Idée JM, Port M, Robic C, Medina C, Sabatou M, Corot C.
    J Magn Reson Imaging; 2009 Dec 27; 30(6):1249-58. PubMed ID: 19938037
    [Abstract] [Full Text] [Related]

  • 5. Nephrogenic systemic fibrosis.
    Weinreb JC, Kuo PH.
    Magn Reson Imaging Clin N Am; 2009 Feb 27; 17(1):159-67. PubMed ID: 19364606
    [Abstract] [Full Text] [Related]

  • 6. The role of gadolinium chelates in the mechanism of nephrogenic systemic fibrosis: A critical update.
    Idée JM, Fretellier N, Robic C, Corot C.
    Crit Rev Toxicol; 2014 Nov 27; 44(10):895-913. PubMed ID: 25257840
    [Abstract] [Full Text] [Related]

  • 7. Gadolinium-associated nephrogenic systemic fibrosis.
    Schlaudecker JD, Bernheisel CR.
    Am Fam Physician; 2009 Oct 01; 80(7):711-4. PubMed ID: 19817341
    [Abstract] [Full Text] [Related]

  • 8. Gadolinium-based contrast agents and nephrogenic systemic fibrosis: why did it happen and what have we learned?
    Weinreb JC, Abu-Alfa AK.
    J Magn Reson Imaging; 2009 Dec 01; 30(6):1236-9. PubMed ID: 19938035
    [Abstract] [Full Text] [Related]

  • 9. Nephrogenic systemic fibrosis and its impact on abdominal imaging.
    Prince MR, Zhang HL, Prowda JC, Grossman ME, Silvers DN.
    Radiographics; 2009 Oct 01; 29(6):1565-74. PubMed ID: 19959508
    [Abstract] [Full Text] [Related]

  • 10. Nephrogenic systemic fibrosis: more questions and some answers.
    Morcos SK, Thomsen HS.
    Nephron Clin Pract; 2008 Oct 01; 110(1):c24-31; discussion c32. PubMed ID: 18688172
    [Abstract] [Full Text] [Related]

  • 11. Gadolinium-associated nephrogenic systemic fibrosis: the need for nephrologists' awareness.
    Canavese C, Mereu MC, Aime S, Lazzarich E, Fenoglio R, Quaglia M, Stratta P.
    J Nephrol; 2008 Oct 01; 21(3):324-36. PubMed ID: 18587720
    [Abstract] [Full Text] [Related]

  • 12. Nephrogenic systemic fibrosis: possible mechanisms and imaging management strategies.
    Dawson P.
    J Magn Reson Imaging; 2008 Oct 01; 28(4):797-804. PubMed ID: 18821621
    [No Abstract] [Full Text] [Related]

  • 13. Nephrogenic systemic fibrosis: the need for accurate case reporting.
    Spinazzi A, Kirchin MA, Pirovano G.
    J Magn Reson Imaging; 2009 May 01; 29(5):1240; author reply 1241. PubMed ID: 19388104
    [No Abstract] [Full Text] [Related]

  • 14. Nephrogenic systemic fibrosis: a gadolinium-associated fibrosing disorder in patients with renal dysfunction.
    Kay J.
    Ann Rheum Dis; 2008 Dec 01; 67 Suppl 3():iii66-9. PubMed ID: 19022818
    [Abstract] [Full Text] [Related]

  • 15. Nephrogenic systemic fibrosis: pathogenesis, diagnosis, and therapy.
    Kribben A, Witzke O, Hillen U, Barkhausen J, Daul AE, Erbel R.
    J Am Coll Cardiol; 2009 May 05; 53(18):1621-8. PubMed ID: 19406336
    [Abstract] [Full Text] [Related]

  • 16. Current status of gadolinium toxicity in patients with kidney disease.
    Perazella MA.
    Clin J Am Soc Nephrol; 2009 Feb 05; 4(2):461-9. PubMed ID: 19201920
    [Abstract] [Full Text] [Related]

  • 17. How to avoid nephrogenic systemic fibrosis: current guidelines in Europe and the United States.
    Thomsen HS.
    Radiol Clin North Am; 2009 Sep 05; 47(5):871-5, vii. PubMed ID: 19744601
    [Abstract] [Full Text] [Related]

  • 18. Nephrogenic systemic fibrosis: clinical spectrum of disease.
    Mayr M, Burkhalter F, Bongartz G.
    J Magn Reson Imaging; 2009 Dec 05; 30(6):1289-97. PubMed ID: 19937929
    [Abstract] [Full Text] [Related]

  • 19. Gadolinium-containing MRI contrast agents: important variations on a theme for NSF.
    Kuo PH.
    J Am Coll Radiol; 2008 Jan 05; 5(1):29-35. PubMed ID: 18180006
    [Abstract] [Full Text] [Related]

  • 20. Toxicity of contrast media: an update.
    ten Dam MA, Wetzels JF.
    Neth J Med; 2008 Nov 05; 66(10):416-22. PubMed ID: 19011267
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.